Medpace Holdings  (NASDAQ: MEDP) and Doximity (NYSE: DOCS) hold unique spots in the healthcare industry, with Medpace being a Top-10 clinical contract research organization (CRO) and Doximity being the best way for advertisers to reach physicians. 

Both companies have sound financials, with growing revenue and earnings per share and very little debt. They appear to have good potential as long-term investments, too. But which one of the two is a better buy this year?

Medpace Holdings has more than 5,000 employees across 41 countries. It helps manage other companies' clinical trials, providing development services to healthcare companies. The Cincinnati-based company has grown quarterly revenue by 285% over the past 10 years, and its shares are up more than 12% over the past year. 

Continue reading

Source Fool.com